Amicus Therapeutics (FOLD) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics or view top-rated stocks.

5 Wall Street analysts have issued 1 year target prices for Amicus Therapeutics' shares. Their FOLD stock forecasts range from $14.00 to $16.00. On average, they predict Amicus Therapeutics' share price to reach $15.25 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts' price targets for Amicus Therapeutics or view top-rated stocks among Wall Street analysts.

Amicus Therapeutics' stock was trading at $11.55 at the beginning of 2022. Since then, FOLD shares have increased by 5.5% and is now trading at $12.18.
View the best growth stocks for 2022 here.

Amicus Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 21,750,000 shares, a decline of 18.5% from the June 30th total of 26,700,000 shares. Based on an average trading volume of 3,850,000 shares, the short-interest ratio is presently 5.6 days.
View Amicus Therapeutics' Short Interest.

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our earnings forecast for Amicus Therapeutics.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative trailing twelve-month return on equity of 91.37%. During the same period in the prior year, the firm posted ($0.19) EPS.

Amicus Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $350.00 million-$365.00 million, compared to the consensus revenue estimate of $355.01 million.

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (0.30%), Peregrine Capital Management LLC (0.28%), Integral Health Asset Management LLC (0.25%), DekaBank Deutsche Girozentrale (0.08%), Transcend Capital Advisors LLC (0.07%) and Mirae Asset Global Investments Co. Ltd. (0.06%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $12.18.

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.41 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250,460,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

Amicus Therapeutics employs 496 workers across the globe.

Amicus Therapeutics was founded in 2002.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for Amicus Therapeutics is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.